Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial (Q36707077)

From Wikidata
Jump to navigation Jump to search
scientific article published on 21 December 2015
edit
Language Label Description Also known as
English
Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial
scientific article published on 21 December 2015

    Statements

    Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial (English)
    0 references
    0 references
    0 references
    0 references
    0 references
    0 references
    Nicholas D James
    Malcolm D Mason
    Alastair W S Ritchie
    Christopher C Parker
    J Martin Russell
    Mymoona Alzouebi
    Sharon Beesley
    Susannah Brock
    Richard Cathomas
    Stephanie Gibbs
    Angus J Robinson
    Rajaguru Srinivasan
    John Staffurth
    Santhanam Sundar
    STAMPEDE investigators

    Identifiers

     
    edit
      edit
        edit
          edit
            edit
              edit
                edit
                  edit
                    edit